Biochemical and Biophysical Research Communications
PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma
Introduction
Gallbladder carcinoma (GBC) patients with atypical symptoms at an early stage are usually diagnosed at a locally advanced or metastatic stage, where conventional chemotherapies remain a mainstay [[1], [2], [3]]. However, limited responses to chemotherapies and a lack of effective targeted therapies result in unsatisfactory survival outcomes in advanced GBC [4,5]. Thus, the mechanisms underlying chemotherapy resistance and strategies for chemotherapy resensitization together with novel potential therapeutic targets urgently need to be studied in GBC.
GEM plus a platinum-based drug serves as the most prevalent chemotherapy scheme in the treatment of advanced GBC in both inoperative patients and those with a high risk of postoperative recurrence [1]. As reported, acquired resistance to GEM and platinum-based drugs in GBC involves disordered drug efflux systems marked by abnormal upregulations of ABC family genes [6], as witnessed in other cancers [7,8]. Nevertheless, therapeutic options for overcoming chemotherapy resistance are absent for these molecular indications. More strategies, especially those associated with specific and druggable targets, against chemotherapy-resistant GBC need to be developed.
Developing novel therapeutic strategies against GBC is also necessary for improving clinical outcomes. Recently, immune checkpoint blockade in the form of PD-1/PD-L1 inhibitors has become the most promising therapeutic option for GBC [9,10]. Of interest, PD-1/PD-L1 blockade has a tight link with chemotherapy efficacy. The positive responses to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC [11] suggest that sequential schemes involving PD-1/PD-L1 inhibitors followed by chemotherapy can beneficially result in immunotherapy-activated chemotherapy sensitivity in cancers. Additionally, acquired chemotherapy resistance can be initiated by PD-L1, and the combination of PD-1/PD-L1 inhibitors with chemotherapy is a promising therapeutic option for treating chemotherapy-resistant NSCLC [12,13]. However, the role of PD-L1 in chemotherapy resistance in GBC remains unclear. In addition, upstream regulators of PD-L1 expression are often considered better candidates for PD-1/PD-L1 blockade-containing combination strategies in cancers [14,15]. Thus, identifying novel molecules upstream of PD-L1 is of significance in GBC. Apart from PD-1/PD-L1 inhibitors, there are almost no novel therapeutic targets found in GBC. Thus, novel molecular targets, especially those related to PD-L1 levels and chemotherapy resistance, deserve and in-depth analysis in GBC.
In this work, we identified a novel potential molecular biomarker, placenta-specific protein 8 (PLAC8), that is highly expressed in GBC using TMAs of surgical specimens. We then examined the relationship of PLAC8 levels with PD-L1 expression in GBC tissues as well as their roles in chemotherapy resistance using our established GEM-resistant and OXA-resistant GBC preclinical models. Our work sheds light on the therapeutic potential of targeting PLAC8 and PD-L1 in GBC, especially in chemotherapy-resistant patients.
Section snippets
Cell culture
The human gallbladder carcinoma cell line SGC996 was purchased from the Cell Bank of the Chinese Academy of Sciences. Cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1x penicillin-streptomycin (HyClone) at 37 °C in a humidified 5% CO2 atmosphere.
Establishment of drug-resistant cells
For up to 2 months, SGC996 cells were treated with GEM at concentrations ranging from 5 μM to 40 μM or OXA at concentrations ranging from 2 μM to 20 μM; the resulting drug-resistant cells were named SGC996GR
PLAC8 protein expression was higher in tumor tissues than in adjacent normal tissues and positively correlated with PD-L1 expression in GBC
PLAC8, an oncogene, is universally overexpressed among various cancer types and can serve as a prognostic biomarker to predict poor prognosis [[17], [18], [19], [20], [21]]. However, the expression of PLAC8 in GBC remains uninvestigated. Thus, PLCA8 expression was evaluated in 20 pairs of GBC tissues and normal tissues arranged in TMAs. Similar to published results [22], PLAC8 was primarily expressed in the cytosol in GBC tissues (Fig. 1a). Of the evaluable samples, one GBC sample (5%) showed
Discussion
The majority of patients with GBC are diagnosed at an advanced stage, with a 5-year survival rate of approximately 5%, and limited therapeutic options are available for them [2,3]. Chemotherapies, typically GEM and platinum-based drugs, are common therapy options and benefit patients to some extent, but chemotherapy resistance is frequently a challenge [1,5]. Thus, novel therapeutic targets and relevant treatment strategies that target the mechanisms underlying chemotherapy resistance should be
Data availability
The assays used to support the findings of this study are included within the article.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Acknowledgements
This work was supported by Zhongshan Hospital, Biliary Tract Diseases Institute, Fudan University, Shanghai 200032, P. R. China.
References (34)
- et al.
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
Lancet Oncol.
(2014) - et al.
Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer
J. Thorac. Oncol.
(2018) - et al.
Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression
Cell Rep.
(2014) - et al.
Identification and characterization of a novel multifunctional placenta specific protein 8 in Dugesia japonica
Gene
(2017) - et al.
Induction of Plac8 promotes pro-survival function of autophagy in cadmium-induced prostate carcinogenesis
Cancer Lett.
(2017) - et al.
Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours
Eur. Urol.
(2011) - et al.
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
Blood
(2013) - et al.
Systematic review of management of incidental gallbladder cancer after cholecystectomy
Br. J. Surg.
(2019) Gallbladder carcinoma: prognostic factors and therapeutic options
World J. Gastroenterol.
(2015)- et al.
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
Cancer Sci.
(2018)
Surgical treatment of gallbladder carcinoma: a critical review
Updates Surg
Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation
Oncol. Rep.
An ABC transporter with a secondary-active multidrug translocator domain
Nature
Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
Nature
Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
Gut
Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy
Histopathology
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies
Transl. Lung Cancer Res.
Cited by (14)
Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma
2020, Biochemical and Biophysical Research CommunicationsCitation Excerpt :However, a study demonstrated that only 36% GBC patients responds to gemcitabine treatment predominately due to chemotherapy resistance [4]. For now, both targeted therapies and responsive chemotherapies for advanced GBC are limited [5]. Hence, it is of huge importance to understand the mechanisms that causes chemotherapy resistance and develop novel strategies to overcome the resistance to improve the overall survival of GBC patients.
Updates and advances in the concept of gallbladder cancer treatment
2023, Zhonghua Wai Ke Za Zhi / Chinese Journal of SurgeryNon-coding RNAs as potential biomarkers of gallbladder cancer
2023, Clinical and Translational OncologyCurrent insight into the regulation of PD-L1 in cancer
2022, Experimental Hematology and Oncology
- 1
Both authors have contributed equally to this work.